All In Biotech

Drug Trial Radar · NCT05122182

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

An Investigator Initiated, International Multi-Centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Last checked: Nov 19, 2026Latest source record: Sep 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

49

Actual

Start

Jan 7, 2022

Primary completion

Aug 15, 2022

Study completion Jan 28, 2023

Sponsor

Lead sponsor
University of SydneyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The George Institute
First posted
Nov 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CLARITY 2.0 is an investigator-initiated trial that will evaluate the safety and efficacy of dual treatment with repagermanium, a CCR2 antagonist, and candesartan, an ARB, in patients hospitalised with COVID-19 disease.

Conditions

  • COVID-19
  • SARS-CoV2 Infection

Interventions

  • Candesartan CilexetilDrug

    Angiotensin Receptor Blocker (ARB)

  • RepagermaniumDrug

    C-C chemokine receptor type 2 (CCR2) antagonist

  • Candesartan PlaceboDrug

    Angiotensin Receptor Blocker (ARB) placebo

  • Repagermanium PlaceboDrug

    C-C chemokine receptor type 2 (CCR2) antagonist placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Health Score at day 14Time frame: 14 days

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Jawaharlal Nehru Medical College and Hospital

    Aligarh, India

  • Government Medical College and Hospital

    Chandigarh, India

  • Samishta Hospital and Research Institute

    Guntur, India

  • Maharaja Agrasen Hospital

    Jaipur, India

  • Amrita Institute of Medical Science

    Kochi, India

  • Kasturba Medical College

    Mangaluru, India

  • DM Wayanad Institute of Medical Sciences

    Meppādi, India

  • Sterling Hospital

    Nigdi, India

  • Jivanrekha Multi-Speciality Hospital

    Pune, India

  • All India Institute of Medical Sciences, Raipur

    Raipur, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.